Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.

Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition.

The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation.

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.

Chronic growth hormone administration does not suppress endogenous growth hormone secretion in patients with neurosecretory growth hormone dysfunction.

Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.

Galanin does not affect the growth hormone-releasing hormone-stimulated growth hormone secretion in patients with hyperthyroidism.

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.

Enhanced growth hormone responses to growth hormone releasing hormone in male type I diabetic patients.

Increased growth hormone responses to growth hormone releasing hormone and thyrotropin releasing hormone in patients with metastatic testicular cancer.

Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects.

Growth hormone and prolactin responses to thyrotropin-releasing hormone in patients with severe liver disease.

Triiodothyronine administration reduces serum growth hormone levels and growth hormone responses to thyrotropin-releasing hormone in patients with anorexia nervosa.

The growth hormone response to growth hormone releasing hormone in patients previously treated with bilateral adrenalectomy alone for Cushing's disease.

Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.

Endocrine responses to growth hormone releasing hormone and corticotropin releasing hormone in early-onset Alzheimer's disease.

The 20,000 Da variant of human growth hormone does not bind to growth hormone receptors in human liver.

Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release.

Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome.

Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression.

Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.

Growth hormone response to acute growth hormone releasing hormone administration in uraemic patients on haemodialysis.

Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement.

Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.

Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?

Suggest Documents

Pyridostigmine does not reverse dexamethasone-induced growth hormone inhibition.

The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation.

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.

Chronic growth hormone administration does not suppress endogenous growth hormone secretion in patients with neurosecretory growth hormone dysfunction.

Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.

Galanin does not affect the growth hormone-releasing hormone-stimulated growth hormone secretion in patients with hyperthyroidism.

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.

Enhanced growth hormone responses to growth hormone releasing hormone in male type I diabetic patients.

Increased growth hormone responses to growth hormone releasing hormone and thyrotropin releasing hormone in patients with metastatic testicular cancer.

Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects.

Growth hormone and prolactin responses to thyrotropin-releasing hormone in patients with severe liver disease.

Triiodothyronine administration reduces serum growth hormone levels and growth hormone responses to thyrotropin-releasing hormone in patients with anorexia nervosa.

The growth hormone response to growth hormone releasing hormone in patients previously treated with bilateral adrenalectomy alone for Cushing's disease.

Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.

Endocrine responses to growth hormone releasing hormone and corticotropin releasing hormone in early-onset Alzheimer's disease.

The 20,000 Da variant of human growth hormone does not bind to growth hormone receptors in human liver.

Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release.

Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome.

Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression.

Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.

Growth hormone response to acute growth hormone releasing hormone administration in uraemic patients on haemodialysis.

Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement.

Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.

Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?

Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.

Recommend Documents

Follow Us